KR102475124B1 - sGC 자극제를 사용한 CNS 질환의 치료 - Google Patents

sGC 자극제를 사용한 CNS 질환의 치료 Download PDF

Info

Publication number
KR102475124B1
KR102475124B1 KR1020197016351A KR20197016351A KR102475124B1 KR 102475124 B1 KR102475124 B1 KR 102475124B1 KR 1020197016351 A KR1020197016351 A KR 1020197016351A KR 20197016351 A KR20197016351 A KR 20197016351A KR 102475124 B1 KR102475124 B1 KR 102475124B1
Authority
KR
South Korea
Prior art keywords
disorder
cns
disease
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016351A
Other languages
English (en)
Korean (ko)
Other versions
KR20190094167A (ko
Inventor
준 정
토마스 와이-호 리
라제쉬 알. 아이옌가
니콜라스 로버트 펄
피터 게르마노
마리아 디. 리바데네이라
킴 탕
Original Assignee
사이클리온 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이클리온 테라퓨틱스, 인크. filed Critical 사이클리온 테라퓨틱스, 인크.
Publication of KR20190094167A publication Critical patent/KR20190094167A/ko
Application granted granted Critical
Publication of KR102475124B1 publication Critical patent/KR102475124B1/ko
Assigned to 티센토 쎄라퓨틱스 인크. reassignment 티센토 쎄라퓨틱스 인크. 권리의 전부이전등록 Assignors: 사이클리온 테라퓨틱스, 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197016351A 2016-11-08 2017-11-07 sGC 자극제를 사용한 CNS 질환의 치료 Active KR102475124B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
US62/419,059 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Publications (2)

Publication Number Publication Date
KR20190094167A KR20190094167A (ko) 2019-08-12
KR102475124B1 true KR102475124B1 (ko) 2022-12-08

Family

ID=60452769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016351A Active KR102475124B1 (ko) 2016-11-08 2017-11-07 sGC 자극제를 사용한 CNS 질환의 치료

Country Status (18)

Country Link
US (4) US11690828B2 (enExample)
EP (1) EP3538096B1 (enExample)
JP (2) JP7150740B2 (enExample)
KR (1) KR102475124B1 (enExample)
CN (1) CN110267658B (enExample)
AU (2) AU2017359018C1 (enExample)
BR (1) BR112019009449A2 (enExample)
CA (1) CA3042548A1 (enExample)
CL (1) CL2019001256A1 (enExample)
EA (1) EA201991147A1 (enExample)
ES (1) ES2972711T3 (enExample)
IL (1) IL266275B2 (enExample)
MA (1) MA46752A (enExample)
MX (2) MX2019005342A (enExample)
PH (1) PH12019501016A1 (enExample)
SG (1) SG10202104865UA (enExample)
TW (1) TWI812601B (enExample)
WO (1) WO2018089328A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089330A2 (en) * 2016-11-08 2018-05-17 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
JP2023505329A (ja) * 2019-12-05 2023-02-08 ザイダス・ライフサイエンシーズ・リミテッド リオシグアトの放出調節医薬組成物
WO2021158059A1 (ko) 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
EP4326268A1 (en) * 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Treatment of cns diseases with sgc stimulators
WO2023130028A1 (en) * 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
CN120752026A (zh) * 2023-02-03 2025-10-03 R·P·谢勒技术有限公司 渗透药用胶囊

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004235A1 (en) 2006-04-27 2010-01-07 Bayer Healthcare Ag Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3660408D1 (en) 1985-02-27 1988-08-25 Oerlikon Buehrle Ag Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100720844B1 (ko) 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20060033033A (ko) 2003-08-04 2006-04-18 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
US7947664B2 (en) 2008-01-24 2011-05-24 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2019502686A (ja) * 2015-12-14 2019-01-31 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化管括約筋機能障害の治療へのｓＧＣ刺激薬の使用
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
EP3872080B1 (en) * 2016-09-02 2023-08-16 Cyclerion Therapeutics, Inc. Fused bicyclic sgc stimulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004235A1 (en) 2006-04-27 2010-01-07 Bayer Healthcare Ag Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 21(21), 6515-6518, 2011.*
Future Med. Chem., 5(12), 1451-1468, 2013.

Also Published As

Publication number Publication date
IL266275B1 (en) 2023-08-01
AU2017359018C1 (en) 2023-12-21
NZ753434A (en) 2025-10-31
CN110267658B (zh) 2024-02-02
JP2019534327A (ja) 2019-11-28
WO2018089328A8 (en) 2019-03-28
US20260000653A1 (en) 2026-01-01
ES2972711T3 (es) 2024-06-14
SG10202104865UA (en) 2021-06-29
AU2017359018A1 (en) 2019-05-30
MX2022010852A (es) 2022-09-27
AU2017359018B2 (en) 2023-08-31
IL266275B2 (en) 2023-12-01
KR20190094167A (ko) 2019-08-12
IL266275A (en) 2019-06-30
TW201822765A (zh) 2018-07-01
EP3538096A1 (en) 2019-09-18
WO2018089328A1 (en) 2018-05-17
MA46752A (fr) 2019-09-18
CN110267658A (zh) 2019-09-20
TWI812601B (zh) 2023-08-21
CL2019001256A1 (es) 2019-10-04
CA3042548A1 (en) 2018-05-17
US20250108040A1 (en) 2025-04-03
US20190343813A1 (en) 2019-11-14
MX2019005342A (es) 2019-10-02
EP3538096C0 (en) 2024-02-28
JP2022160605A (ja) 2022-10-19
EP3538096B1 (en) 2024-02-28
BR112019009449A2 (pt) 2019-07-30
PH12019501016A1 (en) 2019-09-09
EA201991147A1 (ru) 2019-11-29
US11690828B2 (en) 2023-07-04
AU2023270267A1 (en) 2023-12-07
US20230381153A1 (en) 2023-11-30
JP7150740B2 (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
JP7628096B2 (ja) 縮合二環式ｓｇｃ刺激剤
US20260000653A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
US20240132528A1 (en) Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators
WO2017106175A2 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
HK40013531A (en) Treatment of cns diseases with sgc stimulators
HK40013531B (en) Treatment of cns diseases with sgc stimulators
HK40061428B (en) Fused bicyclic sgc stimulators
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
BR112019004468B1 (pt) Estimulantes de sgc

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190607

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220302

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220602

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220901

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221205

End annual number: 3

Start annual number: 1

PG1601 Publication of registration